LnRiLWZpZWxke21hcmdpbi1ib3R0b206MC43NmVtfS50Yi1maWVsZC0tbGVmdHt0ZXh0LWFsaWduOmxlZnR9LnRiLWZpZWxkLS1jZW50ZXJ7dGV4dC1hbGlnbjpjZW50ZXJ9LnRiLWZpZWxkLS1yaWdodHt0ZXh0LWFsaWduOnJpZ2h0fS50Yi1maWVsZF9fc2t5cGVfcHJldmlld3twYWRkaW5nOjEwcHggMjBweDtib3JkZXItcmFkaXVzOjNweDtjb2xvcjojZmZmO2JhY2tncm91bmQ6IzAwYWZlZTtkaXNwbGF5OmlubGluZS1ibG9ja311bC5nbGlkZV9fc2xpZGVze21hcmdpbjowfQ==
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
Inhaled amphotericin, a antifungal drug would decrease Aspergillus colonization and decrease the occurrence of exacerbations of Allergic Bronchopulmonary Aspergillosis (ABPA).
Allergic Bronchopulmonary Aspergillosis |
Drug: Inhaled budesonide
Drug: Inhaled amphotericin |
Phase 2
Phase 3 |
Study Type: |
Interventional |
Study Design: |
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment |
Date of article/Start date of trial: 13 May 2013
Trial Phase: Phase 3
clinical Trials Gov ID: NCT01857479
Trial status: Completed